Wall Street analyst estimates for MediciNova, Inc. (MNOV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $4.0M | 0 | $1.0M | 0 | $409657 |
| Cost of Revenue | $14127 | $28098 | $25881 | $23944 | 0 | 0 | 0 | 0 | 0 | $378606 |
| Gross Profit | -$14127 | -$28098 | -$25881 | -$23944 | 0 | $4.0M | 0 | $1.0M | 0 | $31051 |
| Research & Development | $3.5M | $4.2M | $5.6M | $6.1M | $7.5M | $8.1M | $9.1M | $5.7M | $7.2M | $7.2M |
| Selling, General & Admin | $7.4M | $8.8M | $10.0M | $8.0M | $6.7M | $5.7M | $5.5M | $5.2M | $5.5M | $6.2M |
| Operating Expenses | $10.9M | $13.0M | $15.6M | $14.0M | $14.2M | $14.3M | $14.6M | $10.9M | $12.7M | $13.3M |
| Operating Income | -$10.9M | -$13.0M | -$15.6M | -$14.0M | -$14.2M | -$10.2M | -$14.6M | -$9.9M | -$12.7M | -$13.3M |
| EBITDA | -$10.9M | -$13.0M | -$15.6M | -$14.0M | -$14.2M | -$10.1M | -$14.0M | -$8.5M | -$11.0M | -$12.0M |
| Interest Expense | $454 | $298 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$10.9M | -$12.9M | -$14.7M | -$12.9M | -$13.9M | -$10.1M | -$14.1M | -$8.6M | -$11.0M | -$12.0M |
| Income Tax | $3754 | -$1.7M | $5276 | $12660 | -$1648 | $2568 | $2822 | $3047 | $5537 | $5994 |
| Net Income | -$10.9M | -$11.2M | -$14.7M | -$12.9M | -$13.9M | -$10.1M | -$14.1M | -$8.6M | -$11.0M | -$12.0M |
| EPS | $-0.33 | $-0.32 | $-0.36 | $-0.30 | $-0.31 | $-0.21 | $-0.29 | $-0.17 | $-0.23 | $-0.24 |
| EPS (Diluted) | $-0.33 | $-0.32 | $-0.36 | $-0.30 | $-0.31 | $-0.21 | $-0.29 | $-0.17 | $-0.23 | $-0.24 |
| Shares Outstanding (Diluted) | $33.0M | $35.1M | $41.1M | $43.2M | $44.4M | $48.6M | $49.0M | $49.0M | $49.0M | $49.1M |
Price
| Price | $2.52 |
| Market Cap | $124M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACRV · BMEA · CBUS · FBIO · IMUX · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of MNOV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks